Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Acute Effects of Glucose Dependent Insulinotropic Polypeptide (GIP) on Subcutaneous Adipose Tissue

This study has been completed.
Sponsor:
Collaborator:
German Research Foundation
Information provided by:
German Institute of Human Nutrition
ClinicalTrials.gov Identifier:
NCT00774488
First received: October 16, 2008
Last updated: NA
Last verified: October 2008
History: No changes posted

October 16, 2008
October 16, 2008
January 2006
July 2007   (final data collection date for primary outcome measure)
Changes in gene expression of subcutaneous adipose tissue with microarray analysis [ Time Frame: 3 years ] [ Designated as safety issue: No ]
Same as current
No Changes Posted
Analysis of inflammatory marker (blood levels and gene expression), Activity of 11beta HSD and 11-beta HSD mRNA in adipose tissue, etc. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Acute Effects of Glucose Dependent Insulinotropic Polypeptide (GIP) on Subcutaneous Adipose Tissue
Not Provided

This clinical, randomized, cross-over study in obese healthy subjects aimed to analyse the acute effects of the incretin hormon Glucose Dependent Insulinotropic Polypeptide (GIP) on metabolic parameters and gene expression in subcutaneous adipose tissue.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Single Blind (Subject)
Primary Purpose: Basic Science
  • Metabolic Syndrome
  • Obesity
  • Insulin Sensitivity
Other: Glucose dependent insulinotropic polypeptide (GIP)
GIP-Infusions for 4 h in a postprandial concentration
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
17
July 2007
July 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • BMI > 28
  • Healthy subjects
  • Normal glucose tolerance

Exclusion Criteria:

  • Diabetes,IFG, IGT
  • Chronical-inflammatory diseases
  • Hb < 12g/dl
  • Elevation in liver enzymes or creatinin concentrations
  • Great weight changes within last 12 months
  • Any cancer diagnosis in last 10 years
Male
18 Years to 70 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00774488
GIP-Genexpression Study
Yes
AFH. Pfeiffer, German Institute of Human Nutrition
German Institute of Human Nutrition
German Research Foundation
Not Provided
German Institute of Human Nutrition
October 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP